Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 22;2(3):680-681.
doi: 10.1002/jha2.198. eCollection 2021 Aug.

Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy

David García-Bernal  1 , Edward Richardson  2   3 , Israel Vlodavsky  4 , Carmelo Carlo-Stella  5   6 , Massimo Iacobelli  7 , Rubén Jara  8 , Paul G Richardson  9 , Jose M Moraleda  1
Affiliations

Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy

David García-Bernal et al. EJHaem. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. David Garcia Bernal, Dr. Israel Vlodavsky, and Dr. Massimo Iacobelli have no conflict of interest to declare. Dr. Carmelo Carlo‐Stella has received research support from ADC Therapeutics and Rhizen Pharmaceuticals; has served as consultant or advisor for Servier, Novartis, Genenta Science srl, ADC Therapeutics, Roche, Sanofi, Karyopharm and Jazz Pharmaceuticals; and has received honoraria for speaker engagements from Bristol‐Myers Squibb, Merck Sharp & Dohme, Janssen Oncology, and Astra‐Zeneca. Dr. Ruben Jara declares honorarium from Edwards Lifesciences and Getinge. Dr. Paul Richardson serves on advisory committees for Jazz Pharmaceuticals. Dr. Jose M. Moraleda reports grants from Jazz Pharmaceuticals, during the conduct of the study; consulting honoraria and travel expenses from Gilead, consulting honoraria from Novartis, Sandoz, and Takeda, outside the submitted work.

Similar articles

See all similar articles

Cited by

References

    1. Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID‐19. Am J Hematol. 2020;95:834–47. - PMC - PubMed
    1. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID‐19‐associated coagulopathy: evidence from a single‐centre, cross‐sectional study. Lancet Haematol. 2020;7(8):e575–82. - PMC - PubMed
    1. Levi M, Iba T. COVID‐19 coagulopathy: is it disseminated intravascular coagulation?. Intern Emerg Med. 2021;16(2):309–312. - PMC - PubMed
    1. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID‐19. Lancet. 2020;395(10238):e100. - PMC - PubMed
    1. Koganti R, Suryawanshi R, Shukla D. Heparanase, cell signaling, and viral infections. Cell Mol Life Sci. 2020;May 27:1–19. - PMC - PubMed